| abstract |
The present invention relates to new assays, systems and kits for the selection of a treatment regimen for a subject with depression by identifying at least one nucleic acid polymorphism, for example, but not limited to, in the locus of MTHFR, MTR or MTRR, and / or when determining expression levels of peripheral biomarkers (eg, SAM, SAH and 4-HNE) in a test sample of a human subject. These biomarkers can be used to determine the efficacy of treating a depressed subject with a compound containing folate (alone or as an adjunct to an antidepressant). In addition, these biomarkers can be used to select an appropriate treatment regimen for subjects with treatment-resistant depression (eg, resistant to at least one selective serotonin reuptake inhibitor). Methods and compositions for treating a subject with depression and / or for determining or improving the efficacy of an antidepressant drug taken by a subject are also provided herein. |